Expecting an increase in research and development costs this year, Cardiome Pharma Corp. is raising $51 million in a public offering to continue its clinical programs for atrial fibrillation and congestive heart failure. (BioWorld Today)

Something of a rumble is shaping up in opioid-induced bowel dysfunction, as a pair of companies race to get a drug on the market for the condition. (BioWorld Financial Watch)